Vistagen Therapeutics Files 2024 10-K, Details Pipeline Progress

TL;DR

Vistagen's 2024 10-K is out, showing R&D focus on neuro/psych drugs like PH94B. Keep an eye on trial results!

AI Summary

Vistagen Therapeutics, Inc. filed its 10-K for the fiscal year ending March 31, 2024, reporting on its ongoing development of treatments for neurological and psychiatric disorders. The company's financial performance and strategic initiatives for the period were detailed, including updates on its clinical trial progress and regulatory pathways. Vistagen continues to focus on advancing its pipeline candidates, such as PH94B for anxiety disorders, with significant investments in research and development.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Vistagen's financial health, operational progress, and strategic direction for the past fiscal year, crucial for understanding the company's future prospects in the competitive biopharmaceutical market.

Risk Assessment

Risk Level: high — Biopharmaceutical companies like Vistagen face inherent risks related to clinical trial success, regulatory approvals, and market competition.

Key Numbers

• 2024-03-31 — Fiscal Year End (The period covered by the 10-K filing.)
• 2023-04-01 — Fiscal Year Start (The beginning of the reporting period.)
• 2022-04-01 — Prior Fiscal Year Start (The beginning of the prior reporting period.)

Key Players & Entities

• Vistagen Therapeutics, Inc. (company) — Filer of the 10-K
• PH94B (drug_candidate) — Key pipeline asset for anxiety disorders
• March 31, 2024 (date) — Fiscal year end for the 10-K filing
• 343 Allerton Avenue, South San Francisco, CA 94080 (address) — Company's business and mailing address

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share VTGN The Nasdaq Capital Marke

Filing Documents

• vtgn-20240331.htm (10-K) — 1726KB
• vtgn-exx431.htm (EX-4.31) — 13KB
• vtgn-20230810xexx10163.htm (EX-10.163) — 60KB
• vtgn-exx231x20240611.htm (EX-23.1) — 2KB
• vtgn-20230331xexx311.htm (EX-31.1) — 10KB
• vtgn-20230331xexx312.htm (EX-31.2) — 10KB
• vtgn-20230331xexx321.htm (EX-32.1) — 5KB
• vtgn-20231002xexx971.htm (EX-97.1) — 34KB
• vtgn-20240331_g1.jpg (GRAPHIC) — 124KB
• 0001411685-24-000022.txt ( ) — 7327KB
• vtgn-20240331.xsd (EX-101.SCH) — 52KB
• vtgn-20240331_cal.xml (EX-101.CAL) — 65KB
• vtgn-20240331_def.xml (EX-101.DEF) — 210KB
• vtgn-20240331_lab.xml (EX-101.LAB) — 659KB
• vtgn-20240331_pre.xml (EX-101.PRE) — 437KB
• vtgn-20240331_htm.xml (XML) — 626KB

Risk Factors

Risk Factors 27 1B. Unresolved Staff Comments 79 1C. Cyber Security 73 2 Properties 74 3 Legal Proceedings 80 4 Mine Safety Disclosures 80 PART II 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 81 6 [Reserved] 81 7 Management's Discussion and Analysis of Financial Condition and Results of Operations 82 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 93 8 Financial Statements and Supplementary Data 94 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 118 9A.

Controls and Procedures

Controls and Procedures 118 9B. Other Information 118 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 124 PART III 10 Directors, Executive Officers and Corporate Governance 119 11

Executive Compensation

Executive Compensation 119 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 119 13 Certain Relationships and Related Transactions, and Director Independence 119 14 Principal Account ant Fees and Services 119 PART IV 15 Exhibits and Financial Statement Schedules 120 16 Form 10-K Summary 126 EXHIBIT INDEX 120

SIGNATURES

SIGNATURES 124 ii Table of Contents

Forward-Looking Statements

Forward-Looking Statements Certain statements in this Annual Report on Form 10-K (Annual Report or Report) may constitute "forward-looking statements" for purposes of the federal securities laws, including the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), that involve substantial risks and uncertainties. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are also forward-looking statements. The words "anticipate," "believe," "can," "contemplate," continue," "could," "estimate," "expect," "future," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "strategy," "target," "will," "would," or the negative of these terms or similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Annual Report may include, for example, statements about: the period over which we anticipate our available financial resources will enable us to fund our operating expense; our ability to obtain additional funding for our operations, including funding necessary to complete further development, approval and, if approved, commercialization of our product candidates; the format, objectives, strategy, likelihood of success, and cost of our preclinical studies and clinical trials and other product development activities, including the design of our preclinical studies and clinical trials; the timing of initiation of our preclinical studies and clinical trials; our ability to recruit an

Business

Item 1. Business Overview We are a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on our deep understanding of nose-to-brain neurocircuitry. Our clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Designed exclusively as nasal sprays, each of our pherine product candidates is centered on our innovative approach to addressing neuroscience disorders with the nose as a new portal for the administration of novel, rapid-onset neuroactive therapies that do not require systemic absorption or binding to neurons in the brain to achieve desired therapeutic effects. Microgram-level doses of our pherine nasal sprays rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain with a differentiated safety profile observed in all clinical studies completed to date. Our goal is to develop and commercialize a broad and diversified pipeline of innovative neuroactive pherine therapies for multiple highly prevalent neuroscience indications, such as social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) associated with menopause, with limited or inadequate current treatment options to meet the needs of millions of underserved patients in the U.S. and worldwide. See "Our Neuroscience Pipeline" below. Our Strategy As we pursue our goal to efficiently develop and commercialize novel, differentiated neuroactive pherine therapies for psychiatric and neurological disorders, our primary strategy is as follows: Target High-Growth Neuroscience Markets : Pursue commercially attractive, high-prevalence, high-growth neuroscience markets with limited differentiated FDA-approved treatment options, as to both efficacy and safety, and an inadequat

View Full Filing

View this 10-K filing on SEC EDGAR